Biosyent (RX) Set to Announce Earnings on Wednesday

Biosyent (CVE:RX) is set to post its quarterly earnings results before the market opens on Wednesday, May 29th. Analysts expect Biosyent to post earnings of C$0.08 per share for the quarter.

Biosyent (CVE:RX) last announced its quarterly earnings data on Wednesday, March 20th. The company reported C$0.11 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of C$0.11. The firm had revenue of C$5.91 million during the quarter, compared to analyst estimates of C$6.40 million.

Shares of Biosyent stock opened at C$8.15 on Monday. The firm has a market capitalization of $114.89 million and a PE ratio of 20.90. Biosyent has a fifty-two week low of C$6.52 and a fifty-two week high of C$10.26.

Separately, Raymond James set a C$10.00 price objective on Biosyent and gave the company an “outperform” rating in a report on Wednesday, May 15th.

ILLEGAL ACTIVITY WARNING: “Biosyent (RX) Set to Announce Earnings on Wednesday” was originally posted by Dakota Financial News and is owned by of Dakota Financial News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at

Biosyent Company Profile

BioSyent Inc, a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company's products include FeraMAX 150, an oral hematinic for the treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository designed to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of non-muscle invasive papillary bladder cancer.

Featured Story: What is the Bid-Ask Spread?

Earnings History for Biosyent (CVE:RX)

Receive News & Ratings for Biosyent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biosyent and related companies with's FREE daily email newsletter.